Campaign—Once Again Streptokinase Trials (COAST) in Acute Ischemic Stroke


Every year, 1.5 million people suffer from stroke worldwide, the leading cause of disability and the second most common cause of death.1 Stroke incidence in developing countries is much higher and is further rising,2 whereas access to effective acute stroke treatment is very limited. Only 1% stroke sufferers in developing countries have access to the highly expensive tissue plasminogen activator (tPA), the only proven and recommended thrombolytic agent for acute ischemic stroke treatment.3


Leave A Reply